Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines

References

• Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020 Apr 7;S0092-8674(20)30338-X. Epub ahead of print. PMID: 32275855; PMCID: PMC7144619. DOI:10.1016/j.cell.2020.03.045
   Google Scholar
• Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 [published online ahead of print, 2020 Apr 16]. Hum Vaccin Immunother. 2020;1–4. DOI:10.1080/21645515.2020.1740560
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013 Nov 1;342(6158):592–598. Erratum in: Science. 2013 Nov 22;342(6161):931. PMID: 24179220; PMCID: PMC4461862.
   PubMed Web of Science ®Google Scholar
• Crank MC, Ruckwardt TJ, Chen M, et al. VRC 317 study team. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019 Aug 2;365(6452):505–509. PMID: 31371616.
   PubMed Web of Science ®Google Scholar
• Ricke DO, Malone RW. Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE). Preprints. 2020;2020030138. DOI:10.20944/preprints202003.0138.v1
   Google Scholar
• van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020 Jul 30. DOI:10.1038/s41586-020-2608-y. Epub ahead of print. PMID: 32731258.
   Google Scholar
• Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020 Apr;26(4):453–455. PMID: 32284614; PMCID: PMC7095036.
   PubMed Web of Science ®Google Scholar
• Mustaffa-Kamal F, Liu H, Pedersen NC, et al. Characterization of antiviral T cell responses during primary and secondary challenge of laboratory cats with feline infectious peritonitis virus (FIPV). BMC Vet Res. 2019 May 22;15(1):165. PMID: 31118053; PMCID: PMC6532132.
   PubMedGoogle Scholar
• La Gruta NL, Turner SJ. T cell mediated immunity to influenza: mechanisms of viral control. Trends Immunol. 2014 Aug;35(8):396–402. Epub 2014 Jul 16. PMID: 25043801.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wan Y, Qiu C, et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8⁺ T cells. Nat Commun. 2015 May 13;6:6833. PMID: 25967273; PMCID: PMC4479016.
   PubMed Web of Science ®Google Scholar
• Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS. Rev Med Virol. 2020 Apr 8;30. Epub ahead of print. PMID: 32267987. DOI:10.1002/rmv.2107
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020 May 1;130(5):2620–2629. PMID: 32217835; PMCID: PMC7190990.
   PubMed Web of Science ®Google Scholar
• Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020 May;80(5):e1–e6. Epub 2020 Mar 19. PMID: 32171869; PMCID: PMC7102530.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhang Z, Tian J, et al. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. Ann Palliat Med. 2020 Mar 9; 2:428–436. Epub 2020 Mar 17. PMID: 32233642. DOI:10.21037/apm.2020.03.26
   Google Scholar
• Channappanavar R, Fett C, Zhao J, et al. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014 Oct;88(19):11034–11044. Epub 2014 Jul 23. PMID: 25056892; PMCID: PMC4178831.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chu H, Li C, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis. 2014 May 1;209(9):1331–1342. Epub 2013 Sep 24. PMID: 24065148; PMCID: PMC7107356.
   PubMed Web of Science ®Google Scholar
• Yang LT, Peng H, Zhu ZL, et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol. 2006 Aug;120(2):171–178. Epub 2006 Jun 16. PMID: 16781892; PMCID: PMC7106132.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, et al. Rotavirus efficacy and safety trial (REST) study team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006 Jan 5;354(1):23–33. PMID: 16394299.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Sidney J, Zhang Y, et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020 Mar 12. S1931-3128(20)30166–9. Epub ahead of print. PMID: 32183941. DOI:10.1016/j.chom.2020.03.002
   PubMed Web of Science ®Google Scholar
• Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020 Jul 15;584(7821):457–462. Epub ahead of print. PMID: 32668444.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020 Jun 25;181(7):1489–1501.e15. Epub 2020 May 20. PMID: 32473127; PMCID: PMC7237901.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020 Jun 26;5(48):eabd2071. PMID: 32591408; PMCID: PMC7319493.
   PubMed Web of Science ®Google Scholar
• Braun J, Loyal L, Frentsch M, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv. 2020. DOI:10.1101/2020.04.17.20061440
   Google Scholar
• De Groot AS, Moise L, Terry F, et al. Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools. Front Immunol. 2020 Apr 7;11:442. PMID: 32318055; PMCID: PMC7154102.
   PubMed Web of Science ®Google Scholar
• Kalita P, Padhi AK, Zhang KYJ, et al. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2 [published online ahead of print, 2020 May 4]. Microb Pathog. 2020;145:104236.
   PubMed Web of Science ®Google Scholar